Monitor first quarter 2026 financial results for updated guidance on the distribution arrangement's impact. The $5 million fee represents significant upfront investment with potential for revenue growth in the $2 billion hemostatic market.
Price Chart
Executive Summary
Xtant Medical signed an exclusive U.S. distribution agreement for Dilon's HEMOBLAST Bellows product, hiring 20 sales staff and paying a $5 million exclusivity fee. This expands Xtant's portfolio into the $2 billion hemostatic market but involves significant upfront costs.
Key Facts
- Entered exclusive U.S. distribution agreement for HEMOBLAST Bellows product
- Hired approximately 20 Dilon sales personnel
- Paid $5 million exclusivity fee to Dilon
- No minimum purchase requirements for Xtant
- Dilon will continue manufacturing in France
- Product transition and customer contracts to be assigned to Xtant
Financial Impact
XTNT paid $5,000,000 exclusivity fee; potential revenue from $2 billion addressable market
Risk Factors
- Success of distribution arrangement depends on market adoption
- Possibility of agreement termination by either party
- Impact on relationships with existing distributors and sales representatives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-016308 |
| Exhibit: ex99-1.htm | 0001493152-26-016308 |
| Document: 0001493152-26-016308-index-headers.html | 0001493152-26-016308 |
| Document: 0001493152-26-016308-index.html | 0001493152-26-016308 |
| Document: 0001493152-26-016308.txt | 0001493152-26-016308 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $0.3200 $0.3380 | ▼ −5.63% | ▼ −6.68% | $0.2751 (+14.03%) |
Apr 13, 2026 28w ago | 8-K | $0.4800 $0.5200 | ▲ +8.33% | ▲ +0.61% | $0.2751 (−42.69%) |
Mar 31, 2026 29w ago | 8-K | $0.5600 $0.5390 | ▼ −3.75% | ▼ −13.17% | $0.2751 (−50.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers